Sensus Healthcare Resumes Common Stock Repurchase Program

On February 11, 2025, Sensus Healthcare, Inc. (NASDAQ: SRTS) announced the revival of its common stock repurchase program, initially authorized in August 2023. The company, based in Boca Raton, Florida, specializes in medical device solutions focused on minimally invasive treatments for oncological and non-oncological skin conditions.

The decision to restart the repurchase program was unveiled by Sensus Healthcare’s Chairman and CEO, Joe Sardano. Sardano highlighted the company’s confidence in its growth trajectory and the belief that acquiring common stock at current prices presents a compelling opportunity. He emphasized the commitment to enhancing shareholder value while also maintaining flexibility for strategic investments.

The newly reintroduced program allows for the repurchase of up to $3.0 million worth of common stock through open-market transactions. Ahead of this relaunch, the company had already repurchased 9,427 shares under the existing program. The specifics of the repurchase activity will be overseen by Sensus Healthcare’s management, guided by ongoing assessments of capital requirements and market conditions.

Sensus Healthcare is a trailblazer in non-invasive treatments for skin cancer and keloids, leveraging advanced radiotherapy technology to offer precise and patient-centric solutions. The company’s innovative approach to radiation oncology aims to provide safe and adaptable treatment options across various clinical settings.

Forward-looking statements included in the recent announcement caution investors about potential risks and uncertainties associated with future developments and economic conditions. Sensus Healthcare continues to monitor industry dynamics closely to adapt to evolving challenges efficiently.

For interested parties seeking further insights into Sensus Healthcare’s operations and offerings, additional information can be accessed at www.sensushealthcare.com.

Please note that any forward-looking statements made by Sensus Healthcare pertain only to the date of the statement and are subject to potential updates as required by law. Interested individuals are encouraged to review the company’s periodic reports filed with the Securities and Exchange Commission to gain a comprehensive understanding of associated risks and uncertainties within the business landscape.

For any inquiries, please contact Alliance Advisors IR:
Tirth T. Patel
Email: [email protected]
Phone: 212-201-6614

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sensus Healthcare’s 8K filing here.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.